Context: In the human fetal adrenal gland (HFA), the inner fetal zone (FZ) secretes dehydroepiandrosterone sulfate. The function of the outer definitive zone (DZ) is less clear; however, the DZ phenotype is that of a reservoir of progenitor cells, many of which are mitotically active. Midkine (MK) is a heparin-binding growth factor with various bioactivities.
Objective: The objective of this study was to investigate expression, proliferative effects, and ACTH regulation of MK in the HFA.
Design And Setting: RNA, cryosections, and primary cell cultures from HFAs (14-24 wk) and adult adrenal RNA were used.
Main Outcome Measures: The main outcome measures were MK mRNA levels (measured by quantitative real-time RT-PCR); MK localization (measured by immunostaining); MK proliferative effects and mechanism (measured by proliferation assays, flow cytometry, pharmacological interventions); and ACTH regulation (measured by quantitative real-time RT-PCR).
Results: HFA MK mRNA levels were 4-fold higher than in adult adrenals (P < 0.05) and were comparable to levels in fetal and adult brains (positive controls). MK immunoreactivity was abundant throughout the HFA. Exogenous MK caused proliferation of isolated DZ cells but not FZ cells (72 h, P < 0.05). In contrast, basic fibroblast growth factor induced proliferation of cells from both zones. Pharmacological interventions indicated that MK-induced DZ cell proliferation may be mediated by phosphatidylinositol 3-kinase, MAPK kinase, and Src family kinases. ACTH (1 nm) increased MK mRNA by 3.5-fold (48 h, P < 0.01) in isolated FZ cells.
Conclusions: MK likely plays a key role in HFA development. MK's selective in vitro mitotic effects on DZ cells may provide insights into the mechanism underlying the distinct in vivo differences in mitotic activity between the DZ and FZ.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/jc.2006-1139 | DOI Listing |
Background: We have previously reported the neuroprotective effects of fosgonimeton in amyloid-β (Aβ)-driven preclinical models of Alzheimer's disease (AD). Fosgonimeton is an investigational small-molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system, currently under investigation for mild-to-moderate AD (LIFT-AD; NCT04488419). Given the recent approvals of Aβ-targeting monoclonal antibodies (Aβ-mAbs) for the treatment of AD, and growing recognition that combination therapies may improve treatment outcomes, we sought to investigate the preclinical activity of fosgonimeton in the presence of Aβ-mAbs.
View Article and Find Full Text PDFBackground: Accumulating evidence highlights impairment of autophagy as a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD). Autophagy is a highly dynamic, lysosome-based degradation process that promotes the clearance of degenerative factors to maintain cellular functions, preserve metabolic integrity, and ensure survival. Impaired autophagic function leads to the abnormal accumulation of autophagic vesicles (i.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China.
Background: Cerebral small vessel disease (CSVD) is one of the most common nervous system diseases. Hypertension and neuroinflammation are considered important risk factors for the development of CSVD and white matter (WM) lesions.
Method: We used the spontaneously hypertensive rat (SHR) as a model of early-onset CSVD and administered epimedium flavonoids (EF) for three months.
Background: A 73-year-old female with a 3 year history of Alzheimer's disease was treated within the protocol of The Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study (ACIST), an IRB approved clinical study registered with clinicaltrials.gov NCT03724136.
Method: The procedure consists of bone marrow aspiration, cell separation using an FDA cleared class 2 device, and intravenous and intranasal administration of the stem cell fraction.
Alzheimers Dement
December 2024
Nova Southeastern Dr. Kiran C. Patel College of Osteopathic Medicine - TBR, Clearwater, FL, USA.
Background: Research heavily suggests that brain-derived neurotrophic factor (BDNF), vital for neuronal growth and plasticity, and cholecystokinin (CCK), a satiety hormone that regulates BDNF levels, are altered in Alzheimer's Disease pathophysiology. Factors such as dysbiosis of gut microbiota and poor food habits may affect CCK and BDNF release and brain function. The objective is to evaluate the effects of dietary habits, gut microbiota, and exercise on BDNF and CCK release in Alzheimer's Disease patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!